StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Stock analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Price Performance

Shares of NASDAQ LPCN opened at $5.15 on Friday. The business’s 50 day moving average is $5.10 and its two-hundred day moving average is $5.64. Lipocine has a 1-year low of $2.38 and a 1-year high of $11.79. The stock has a market capitalization of $27.55 million, a P/E ratio of -6.78 and a beta of 1.18.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, equities research analysts anticipate that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.